Specimen Collection Cards Market to Reach USD 715.4 Million by 2035, driven by Rising Personalized Medicine and Newborn Screening Initiatives | TMR

The global Specimen Collection Cards Market is projected to grow from US$ 441.5 million in 2024 to US$ 715.4 million by 2035, expanding at a compound annual growth rate (CAGR) of 4.5% during the forecast period from 2025 to 2035, according to the latest market assessment. This steady expansion is attributed to the increasing demand for accurate, reliable, and cost-effective biological sample collection methods that are essential to the evolving fields of personalized medicine, genetic testing, and newborn health screening.

Access important conclusions and data points from our Report in this sample -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86803

As healthcare systems worldwide shift toward more decentralized and patient-centric models, specimen collection cards are gaining prominence for their ability to preserve sample integrity while simplifying logistics and reducing costs. These cards have become indispensable in a range of applications, including diagnostics, epidemiological research, forensic investigations, and clinical trials.

Key Market Insights
The market for specimen collection cards is poised for sustained growth, with North America leading in terms of market share and technological adoption. In 2024, the region accounted for 37.5% of the global revenue, supported by advanced diagnostic infrastructure, extensive newborn screening programs, and regulatory frameworks that ensure quality and safety in laboratory testing. Blood-based specimen collection cards continue to dominate, representing 85.4% of the total market share in 2024 due to their widespread use in clinical diagnostics and their high reliability in capturing DNA, RNA, and protein biomarkers.

Key industry participants such as QIAGEN, PerkinElmer, Hemaxis, Danaher Corporation, Eastern Business Forms, Inc., Thermo Fisher Scientific, and Ahlstrom are focusing on product innovation, expansion into emerging markets, and strategic acquisitions to strengthen their market position. The report also indicates that continuous investments in automation, micro-sampling technologies, and next-generation card materials will enhance efficiency and data accuracy in diagnostic workflows.

Market Drivers
Personalized Medicine and Genetic Testing
The rising adoption of personalized medicine and genetic testing has created substantial demand for high-quality, standardized biological specimen collection solutions. Specimen collection cards offer a simple, non-invasive, and scalable approach to collecting, storing, and transporting samples such as blood and saliva while maintaining molecular integrity critical for downstream analysis.

As healthcare transitions from a one-size-fits-all approach to individualized treatment strategies, these cards serve as vital enablers of precision diagnostics. They facilitate large-scale genomic research, reduce logistical challenges in sample management, and support patient participation in decentralized testing programs. Furthermore, their ability to operate effectively in low-resource settings extends the reach of genetic testing to remote and underserved populations.

Regulatory initiatives, such as the Clinical Laboratory Improvement Amendments (CLIA) under the Centers for Medicare & Medicaid Services (CMS), indirectly strengthen the reliability of specimen collection methods by setting rigorous standards for laboratory testing. As a result, the integration of collection cards within clinical and research settings is enhancing diagnostic accuracy, patient outcomes, and overall healthcare efficiency.

Newborn Screening Initiatives
Newborn screening has emerged as a key driver for the global specimen collection cards market, with governments and healthcare organizations increasingly prioritizing early detection of metabolic, genetic, and hormonal disorders. Dried blood spot (DBS) cards, in particular, have become indispensable in these initiatives due to their simplicity, minimal invasiveness, and long-term storage capabilities.

In the United States, nearly 98% of births occur in hospital settings, where newborn screening using DBS cards is standard practice. These cards enable early identification of conditions such as congenital hypothyroidism, and sickle cell disease-allowing timely intervention that can significantly improve long-term health outcomes. Similar initiatives are being adopted globally, with countries such as Australia expanding healthcare budgets to support neonatal programs, increasing from USD 112.7 million in 2024-2025 to USD 122.8 million for 2027-2028.

Moreover, advancements in card materials and analytical sensitivity are expanding the range of detectable conditions. For instance, in Washington State, DBS specimens are used for multiple disease screenings, and parents can request access to their child's stored blood cards for future health monitoring-illustrating growing trust and integration of these tools into public health systems. As newborn screening programs continue to evolve, specimen collection cards will remain an essential foundation for safeguarding infant health worldwide.

Visit our report for a deep dive into key insights and conclusions -

https://www.transparencymarketresearch.com/specimen-collection-cards-market.html

Regional Outlook
North America continues to be the leading region in the global specimen collection cards market, maintaining a dominant market share due to its robust healthcare infrastructure, comprehensive newborn screening programs, and strong focus on early disease detection. The region benefits from high public health awareness, technological innovation, and supportive regulatory oversight that ensures quality standards across the specimen collection process.

In addition, sustained investment in research and development activities, combined with the growing prevalence of chronic and genetic diseases, reinforces North America's position as a hub for innovation in specimen collection technology. The California Department of Public Health (CDPH), for example, stores newborn blood spot cards in state biobanks for authorized research, highlighting the region's commitment to integrating biosample management into broader public health initiatives.

Outside of North America, Asia Pacific is anticipated to experience the fastest growth during the forecast period. This is primarily driven by expanding healthcare infrastructure, rising diagnostic testing capacity, and government-supported screening programs. Countries such as China, India, and Japan are witnessing rapid advancements in decentralized healthcare delivery, further bolstering market adoption across the region.

Key Developments
The competitive landscape of the specimen collection cards market continues to evolve through strategic partnerships, technological innovation, and corporate acquisitions aimed at strengthening product portfolios and global reach.

In October 2025, Ahlstrom completed the acquisition of Eastern Business Forms (EBF), a South Carolina-based leader in fiber-based medical device manufacturing. This acquisition significantly enhances Ahlstrom's capabilities in life sciences and reinforces its commitment to developing sustainable, high-quality materials for biological sample collection and preservation.

In February 2023, Capitainer AB launched a next-generation self-sampling device capable of collecting five times more blood than its previous version. This innovation represents a major advancement in patient-friendly sampling, particularly beneficial for remote testing and longitudinal studies. Such product developments underline the growing emphasis on user convenience, sample precision, and operational efficiency that are defining the next phase of the specimen collection cards industry.

Buy this Premium Research Report and access vital insights and analysis -

https://www.transparencymarketresearch.com/checkout.php?rep_id=86803

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

This release was published on openPR.